Most Recent
A patent battle between Juno Pharmaceuticals and Bristol-Myers Squibb over the blockbuster drug Revlimid has seen both sides suffer early losses, with a judge dismissing strike out and summary dismissal applications by the drug makers.
Generic pharmaceutical company Sandoz has hit back in an intellectual property lawsuit by Merck Sharp & Dohme, filing a cross-claim that seeks to undo an extension of time granted to the US drug manufacturer for a patent relating to its multibillion dollar Januvia and Janumet diabetes drugs.
Lawyerly's Litigation Firms of 2020 delivered significant victories for clients last year in bet-the-company matters, thriving in a tumultuous year that saw courts and litigants adapt to virtual trials and other new norms that are sure to outlast the COVID-19 pandemic.
Neurim Pharmaceuticals can seek limited additional damages in a patent infringement case relating to its insomnia drug Circadin, after a judge granted a mid-trial bid to amend its pleadings against Generic Partners and Apotex.
A judge hearing Pfizer's application for preliminary discovery against Sandoz over its possible launch of an Enbrel biosimilar has found that such an application must be based on a current belief that the applicant could be entitled to relief.
The High Court has ruled that a patentee's rights to control what can be done with a patented product after it is sold are "exhausted" upon sale.
The High Court will hand down its highly anticipated decision in a patent dispute between printer giant Seiko Epson and ink cartridge reseller Calidad on Thursday, a ruling expected to provide clarity on the the rights of businesses to modify patented goods.
The High Court has declined to weigh in on the patentability of software, rejecting e-commerce company Rokt's bid for review of a decision striking down its marketing invention.
IP Australia has appealed a judge's decision to allow four Aristocrat gaming patents to proceed to grant, hoping for another victory after winning two high stakes challenges to software patents before the Full Federal Court.
A judge has trimmed the costs the Commissioner of Patents owes Aristocrat Technologies after the gaming giant successfully appealed a ruling rejecting four of its gaming patents, saying Aristocrat had "over-egged the pudding" by submitting evidence from three experts on the patentability of its inventions.